JP7862437B2 - オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物 - Google Patents

オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物

Info

Publication number
JP7862437B2
JP7862437B2 JP2023565387A JP2023565387A JP7862437B2 JP 7862437 B2 JP7862437 B2 JP 7862437B2 JP 2023565387 A JP2023565387 A JP 2023565387A JP 2023565387 A JP2023565387 A JP 2023565387A JP 7862437 B2 JP7862437 B2 JP 7862437B2
Authority
JP
Japan
Prior art keywords
another embodiment
formula
ring
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516633A (ja
JP2024516633A5 (enExample
Inventor
チェ，ヨンギ
フー，ユエン
ヒューン，ホアン
アクイラ，ブライアン，エム．
ライマー，ブライアン，ケネス
マッジ，インゴ，アンドレアス
ウッズ，ジェームズ，アール．
ペニントン，ルイス，ディー．
ベンツィエン，イョルグ，マーティン
レーマン，ジョナサン，ウォード
ヘール，マイケル，アール．
バリウリン，ローマン，エイ．
Original Assignee
アルカーメス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカーメス，インコーポレイテッド filed Critical アルカーメス，インコーポレイテッド
Publication of JP2024516633A publication Critical patent/JP2024516633A/ja
Publication of JP2024516633A5 publication Critical patent/JP2024516633A5/ja
Application granted granted Critical
Publication of JP7862437B2 publication Critical patent/JP7862437B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023565387A 2021-04-26 2022-04-25 オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物 Active JP7862437B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179616P 2021-04-26 2021-04-26
US63/179,616 2021-04-26
PCT/US2022/026144 WO2022232025A1 (en) 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Publications (3)

Publication Number Publication Date
JP2024516633A JP2024516633A (ja) 2024-04-16
JP2024516633A5 JP2024516633A5 (enExample) 2024-11-27
JP7862437B2 true JP7862437B2 (ja) 2026-05-19

Family

ID=81750587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565387A Active JP7862437B2 (ja) 2021-04-26 2022-04-25 オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物

Country Status (8)

Country Link
US (1) US20240124485A1 (enExample)
EP (1) EP4329877B1 (enExample)
JP (1) JP7862437B2 (enExample)
CN (1) CN117440955A (enExample)
AU (1) AU2022267220A1 (enExample)
CA (1) CA3215210A1 (enExample)
ES (1) ES3062687T3 (enExample)
WO (1) WO2022232025A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584118A (zh) * 2022-11-23 2025-09-02 沃泰克斯药物股份有限公司 食欲素受体2的经取代的大环胺调节剂
JP2026506356A (ja) 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン２受容体アゴニスト
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP2019504098A (ja) 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004536A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) * 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
MX2011004551A (es) * 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US20100152103A1 (en) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
WO2020004536A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists

Also Published As

Publication number Publication date
EP4329877C0 (en) 2026-02-04
EP4329877B1 (en) 2026-02-04
US20240124485A1 (en) 2024-04-18
JP2024516633A (ja) 2024-04-16
WO2022232025A1 (en) 2022-11-03
AU2022267220A1 (en) 2023-10-19
CN117440955A (zh) 2024-01-23
ES3062687T3 (en) 2026-04-13
EP4329877A1 (en) 2024-03-06
CA3215210A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN116615427B (zh) 被取代的大环化合物及相关治疗方法
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
JP7443625B2 (ja) ビシクロヘプタンピロリジンオレキシン受容体アゴニスト
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
JP6663909B2 (ja) オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
EP3634958B1 (en) Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
TW202134229A (zh) 環烷基尿素衍生物
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
WO2010058846A1 (ja) ４，６-ジアミノニコチンアミド化合物
JP7833486B2 (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
WO2016039408A1 (ja) 複素環化合物
EP1572672A1 (en) Benzoxazocines and their use as monoamine-reuptake inhibitors
WO2023249872A1 (en) Substituted fused bicyclic compounds and related methods of treatment
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
HK40108225A (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40108225B (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40106635A (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40106635B (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40119559A (en) Compounds and compositions for treating conditions associated with lpa receptor activity
WO2012115097A1 (ja) グリシントランスポーター阻害物質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862437

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150